1. Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market; 2. AQST-108, a topical epinephrine gel for alopecia areata, shows promise; 3. Libervant, a diazepam buccal film for cluster seizures, has gained orphan drug exclusivity.